Please wait while the formulary information is being retrieved.
PRIMAQUINE (PRIMAQUINE PHOSPHATE)
- Plasmodium vivax malaria
26.3 mg tablet
- 1 tablet (26.3 mg) by oral route once daily
26.3 mg tablet
- 1 tablet (26.3 mg) by oral route once daily
Plasmodium ovale malaria
- 1 tablet (26.3 mg) by oral route once daily for 14 days
- 1 tablet (26.3 mg) by oral route once daily
Plasmodium vivax malaria
- 1 tablet (26.3 mg) by oral route once daily for 14 days
- 1 tablet (26.3 mg) by oral route once daily
Pneumocystis jirovecii pneumonia
- 1 tablet (26.3 mg) by oral route once daily
- 1 tablet (26.3 mg) by oral route once daily for 21 days
- 2 tablets (52.6 mg) by oral route once daily
- 2 tablets (52.6 mg) by oral route once daily for 21 days
- artemether-lumefantrine
- Coartem
- Cuprimine
- Depen Titratabs
- penicillamine
Contraindicated
- None
Severe
Moderate
- None
- Bone marrow depression
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Hemolytic anemia from PK and g6PD deficiencies
- Pregnancy
Contraindicated
- Hemolytic anemia
- Neutropenic disorder
Severe
Moderate
- Bradycardia
- Congenital long QT syndrome
- Hypokalemia
- Hypomagnesemia
- NADH methemoglobin reductase deficiency
- Prolonged QT interval
- Ventricular arrhythmias
PRIMAQUINE (PRIMAQUINE PHOSPHATE)
- Plasmodium vivax malaria
- Hemolytic anemia
- Abdominal pain with cramps
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Methemoglobinemia
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Cardiac arrhythmia
- Leukopenia
Less Severe
- Dizziness
- Pruritus of skin
- Skin rash
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Primaquine Phosphate
- Severity Level:
1
- Additional Notes: No fda category; hemolytic anemia risk in g-6-pd indiv,cdc and who rec avoiding
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Primaquine
Insufficient data available; should not be used if infant has g6Pd deficiency
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available; should not be used if infant has g6Pd deficiency |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Plasmodium vivax malaria | |
| B51 | Plasmodium vivax malaria |
| B51.0 | Plasmodium vivax malaria with rupture of spleen |
| B51.8 | Plasmodium vivax malaria with other complications |
| B51.9 | Plasmodium vivax malaria without complication |
| 0-9 | A-Z |
|---|---|
| B51 | Plasmodium vivax malaria |
| B51.0 | Plasmodium vivax malaria with rupture of spleen |
| B51.8 | Plasmodium vivax malaria with other complications |
| B51.9 | Plasmodium vivax malaria without complication |
Formulary Reference Tool